Investing

Today's Market Winners and Losers

The stock market is down Friday, with the Dow Jones Industrial Average down 0.01%, the Nasdaq down 0.51% and the S&P 500 down 0.27%. Today’s winners include a technology company which has secured financing for a restructuring and a pharmaceutical company whose drug has received positive remarks from European regulators. Today’s losers include a retailer whose ownership remains in limbo and another pharmaceutical company who is selling stock.

These are Friday’s market winners and losers.

Biggest Winners

Shares of Alcatel-Lucent, S.A. (NYSE: ALU) is up 10.29% to $1.21 on trading volume of 9.9 million shares. The firm has secured $2.1 billion in financing for a restructuring plan. The 52-week high is $2.66.

Shares of Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) are up 8.57% to $5.69 on trading volume of 1.9 million shares. European regulators have called for the approval of experimental drug Adasuve, which helps with schizophrenia and bipolar disorder.  The 52-week high is $9.90.

Biggest Losers

Shares of Best Buy Co. Inc. (NYSE: BBY) are down 15.01% to $12.00 on trading volume of 19.1 million shares. The company has extended the deadline for founder Richard Schulze to make a bid for the company to Feb. 28. The 52-week low is $11.28.

Shares of Cytori Therapeutics, Inc. (NASDAQ: CYTX) are down 14.76% to $2.83 on trading volume of 2.4 million shares. The company said it will sell 7 million shares of stock at $2.85 a share. The 52-week low is $1.90.

Samuel Weigley

Follow him on Twitter: SWeigley

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.